Nektar Therapeutics
NKTRHealthcare|Biotechnology|USA
$70.36
-2.55 (-3.50%)
Tangible Book
$19.55
Clinical Trials (61)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07690371 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis | P3 | Recruiting | 510 | RCT, Double-blind | Rezpegaldesleukin, Placebo |
| NCT06136741 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | P2 | Active | 396 | RCT, Double-blind | Rezpegaldesleukin, Placebo |
| NCT05327530 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | Locally Advanced or Metastatic Urothelial Carcinoma | P2 | Active | 256 | RCT, Open-label | Avelumab, Sacituzumab Govitecan, M6223, NKTR-255 |
| NCT06340360 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | Alopecia Areata | P2 | Active | 94 | RCT, Double-blind | Rezpegaldesleukin, Placebo |
| NCT05632809 REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | Lung Cancer | P2 | Recruiting | 39 | Open-label | NKTR-255, Durvalumab |
| NCT05359211 NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | P1 | Active | 27 | Open-label | Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255 |
| NCT04969861 BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | P2P3 | Terminated | 1 | RCT, Open-label | Bempegaldesleukin, Pembrolizumab |
| NCT00370565 Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy. | Diabetes Mellitus, Type 2 | P3 | Completed | 345 | RCT, Open-label | Inhaled Human Insulin |
| NCT04410445 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | Melanoma, Melanoma Stage III | P3 | Terminated | 765 | RCT, Open-label | Bempegaldesleukin, Nivolumab |
| NCT02367820 Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain | Low Back Pain, Chronic Pain | P3 | Completed | 638 | Open-label | NKTR-181 BID tablets |
| NCT03729245 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | P3 | Terminated | 623 | RCT, Open-label | bempegaldesleukin, sunitinib, nivolumab, cabozantinib |
| NCT02915744 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | Metastasis, Breast Cancer | P3 | Completed | 178 | RCT, Open-label | NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel |
| NCT01492101 The BEACON Study (Breast Cancer Outcomes With NKTR-102) | Locally Recurrent Breast Cancer, Metastatic Breast Cancer | P3 | Completed | 852 | RCT, Open-label | NKTR-102, Treatment of Physician's Choice (TPC) |
| NCT01799993 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia | Pneumonia, Bacterial | P3 | Completed | 725 | RCT, Double-blind | Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo |
| NCT02362672 Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain | Low Back Pain, Chronic Pain | P3 | Completed | 1,189 | RCT, Double-blind | NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets |
| NCT03635983 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | Melanoma | P3 | Completed | 783 | RCT, Open-label | NKTR-214, Nivolumab |
| NCT04209114 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer | Bladder Cancer, Bladder Tumor | P3 | Completed | 114 | RCT, Open-label | Nivolumab, Bempegaldesleukin |
| NCT05664217 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | P2P3 | Terminated | 15 | RCT, Double-blind | NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg |
| NCT00856375 NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | Colorectal Cancer | P2 | Completed | 83 | RCT, Open-label | NKTR-102, irinotecan |
| NCT00802945 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer | Tumor, Breast Cancer | P2 | Completed | 70 | RCT, Open-label | NKTR-102, NKTR-102 |
| NCT01021436 Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia | Pneumonia | P2 | Completed | 30 | Open-label | Amikacin inhalation solution (BAY41-6551) |
| NCT02312622 Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC) | P2 | Completed | 27 | Open-label | Pegylated Irinotecan |
| NCT02869295 A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors | Unspecified Adult Solid Tumor, Protocol Specific | P1P2 | Completed | 28 | Open-label | NKTR-214 |
| NCT00123201 Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache | Migraine With Aura, Migraine Without Aura | P2 | Completed | — | RCT, Double-blind | Dronabinol MDI |
| NCT01457118 An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | Malignant Solid Tumor | P2 | Completed | 27 | Open-label | NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2, NKTR-102 50 mg/m2 |
| NCT04936841 Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer | P2 | Terminated | 5 | Open-label | NKTR-214, anti-PD-1 therapy |
| NCT00598975 NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) | Tumor, Colorectal Cancer | P2 | Completed | 18 | Open-label | NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab |
| NCT00600119 A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC) | Opioid Induced Constipation (OIC) | P2 | Completed | 207 | RCT, Double-blind | placebo, NKTR-118 |
| NCT00806156 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | Tumor, Ovarian Cancer | P2 | Completed | 178 | RCT, Open-label | NKTR-102 q14d, NKTR-102 q21d |
| NCT01876446 Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung Carcinoma | P2 | Completed | 38 | Open-label | Pegylated Irinotecan |
| NCT03138889 Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Non-Small Cell Lung Cancer | P1P2 | Terminated | 162 | Open-label | NKTR-214, Pembrolizumab, NKTR-214, NKTR-214, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab |
| NCT00396578 Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation | Ventilator Associated Pneumonia, Respiratory Infection | P2 | Completed | 80 | RCT, Double-blind | aerosolized vancomycin or gentamicin |
| NCT03435640 REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | Melanoma, Merkel Cell Carcinoma | P1P2 | Terminated | 64 | Open-label | NKTR-262, bempegaldesleukin, nivolumab |
| NCT01663012 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas | P2 | Completed | 20 | Open-label | Etirinotecan pegol |
| NCT04433585 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P2 | Completed | 291 | RCT, Double-blind | LY3471851, Placebo |
| NCT04616196 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | P1P2 | Completed | 25 | Open-label | NKTR-255, Cetuximab |
| NCT04730349 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | Ependymoma, Ewing Sarcoma | P1P2 | Terminated | 15 | Open-label | Nivolumab, NKTR-214 |
| NCT04052204 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | P1P2 | Terminated | 3 | Open-label | avelumab, Bempegaldesleukin, talazoparib, enzalutamide |
| NCT01004445 A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS) | Pneumonia | P2 | Completed | 69 | RCT, Double-blind | Amikacin (BAY41-6551), Amikacin (BAY41-6551), Placebo |
| NCT03548467 A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer | Locally Advanced or Metastatic Solid Tumours | P1P2 | Completed | 41 | Open-label | VB10.NEO, Bempegaldesleukin |
| NCT03785925 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | Urinary Bladder Neoplasm, Neoplasm Metastasis | P2 | Completed | 192 | Open-label | Bempegaldesleukin, Nivolumab |
| NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Colitis, Ulcerative | P2 | Terminated | 81 | RCT, Double-blind | LY3471851, Placebo |
| NCT01619839 A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain | Osteoarthritis of the Knee | P2 | Completed | 296 | RCT, Double-blind | NKTR-181, Placebo |
| NCT02983045 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | Melanoma, Renal Cell Carcinoma | P1P2 | Completed | 557 | Open-label | Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab |
| NCT03745807 An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors | Advanced Cancer | P1 | Completed | 3 | Open-label | NKTR-214, Nivolumab |
| NCT04998487 A Single-Dose Study of LY3471851 in Healthy Participants | Healthy | P1 | Completed | 71 | RCT, Open-label | LY3471851 |
| NCT04081350 A Study of LY3471851 in Participants With Eczema | Dermatitis, Atopic | P1 | Completed | 48 | RCT, Double-blind | LY3471851, Placebo |
| NCT04380324 A Study of NKTR-358 (LY3471851) in Healthy Participants | Healthy | P1 | Completed | 100 | RCT, Double-blind | LY3471851, Placebo |
| NCT03556007 A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P1 | Completed | 48 | RCT, Double-blind | LY3471851, Placebo |
| NCT01976143 A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety | Advanced Cancer, Metastatic Solid Tumors | P1 | Completed | 33 | Open-label | NKTR-102 |
| NCT05676749 C-TIL051 in Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | P1 | Terminated | 1 | Open-label | C-TIL051 |
| NCT04119557 A Study of LY3471851 in Participants With Psoriasis | Psoriasis | P1 | Completed | 30 | RCT, Double-blind | Placebo, LY3471851 |
| NCT04133116 A Study of LY3471851 in Healthy Participants | Healthy | P1 | Completed | 36 | RCT, Double-blind | LY3471851, Placebo |
| NCT04955262 A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | Metastatic Melanoma | P1 | Withdrawn | — | Open-label | Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C |
| NCT04540705 A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread | Renal Cell Carcinoma | P1 | Completed | 30 | Open-label | Nivolumab, Axitinib, Cabozantinib |
| NCT03772288 A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | Lymphoma, Non-Hodgkin | P1 | Withdrawn | — | Open-label | TAK-659, NKTR-214 |
| NCT01991678 A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | P1 | Completed | 25 | Open-label | 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102 |
| NCT04646044 A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 | Covid-19, Coronavirus Disease 2019 | P1 | Completed | 30 | RCT, Double-blind | Bempegaldesleukin, Standard of Care |
| NCT03802227 A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users. | Moderate to Severe Chronic Pain | P1 | Terminated | 8 | RCT, Double-blind | NKTR-181, Oxycodone IR |
| NCT05565729 A Phase I Study of LY3471851 in Healthy Participants | Healthy | P1 | Completed | 41 | RCT, Double-blind | LY3471851, Placebo, Levocetirizine |
| NCT04136756 NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | Multiple Myeloma, Non-Hodgkin Lymphoma | P1 | Completed | 30 | Open-label | NKTR-255, NKTR-255 Q21, Rituximab, Daratumumab |